tradingkey.logo

Insulet Corp

PODD
查看详细走势图
289.620USD
-3.260-1.11%
收盘 12/19, 16:00美东报价延迟15分钟
20.37B总市值
82.66市盈率 TTM

Insulet Corp

289.620
-3.260-1.11%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-1.11%

5天

-2.06%

1月

-16.38%

6月

-4.03%

今年开始到现在

+10.94%

1年

+12.89%

查看详细走势图

TradingKey Insulet Corp股票评分

单位: USD 更新时间: 2025-12-19

操作建议

Insulet Corp当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名42/208位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价378.05。中期看,股价处于下降通道。近一个月,市场表现较差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Insulet Corp评分

相关信息

行业排名
42 / 208
全市场排名
120 / 4582
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 27 位分析师
买入
评级
378.047
目标均价
+27.64%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Insulet Corp亮点

亮点风险
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
业绩高增长
公司营业收入稳步增长,连续3年增长58.71%
利润高增长
公司净利润处于行业前列,最新年度总收入2.07B美元
估值合理
公司最新PE估值82.66,处于3年历史合理位
机构减仓
最新机构持股72.07M股,环比减少4.83%
Mairs and Power 公司持仓
明星投资者Mairs and Power 公司持仓,最新持仓市值1.13K

Insulet Corp新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Insulet Corp简介

Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
公司代码PODD
公司Insulet Corp
CEOMcevoy (Ashley)
网址https://www.omnipod.com

常见问题

Insulet Corp(PODD)的当前股价是多少?

Insulet Corp(PODD)的当前股价是 289.620。

Insulet Corp的股票代码是什么?

Insulet Corp的股票代码是PODD。

Insulet Corp股票的52周最高点是多少?

Insulet Corp股票的52周最高点是354.880。

Insulet Corp股票的52周最低点是多少?

Insulet Corp股票的52周最低点是230.050。

Insulet Corp的市值是多少?

Insulet Corp的市值是20.37B。

Insulet Corp的净利润是多少?

Insulet Corp的净利润为418.30M。

现在Insulet Corp(PODD)的股票是买入、持有还是卖出?

根据分析师评级,Insulet Corp(PODD)的总体评级为买入,目标价格为378.047。

Insulet Corp(PODD)股票的每股收益(EPS TTM)是多少

Insulet Corp(PODD)股票的每股收益(EPS TTM)是3.504。
KeyAI